Melanoma, an aggressive malignant tumor originating from melanocytes in humans, is on
the rise globally, with limited non-surgical treatment options available. Recent …

Few studies evaluated patient-reported outcomes (PROs) for patients with hematologic
malignancies receiving with Chimeric Antigen Receptor T (CAR-T) cell therapy. We …

The inclusion of patient-reported outcome (PRO) measures in chimeric antigen receptor
(CAR) T-cell therapy research is critical for understanding the impact of this novel approach …

Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable clinical
responses in hematologic malignancies. Recent advances in CAR T-cell therapy have …

Background Research on depression showed that dysregulations in tryptophan (TRP),
kynurenine (KYN), and its KYN pathway metabolites are key aspects in the development …

A growing body of literature has emphasized the importance of biobehavioral processes–
defined as the interaction of behavior, psychology, socioenvironmental factors, and …

Chimeric antigen receptor (CAR) T-cell therapy utilization has risen sharply in recent years,
becoming a standard approach for refractory B-cell malignancies. 1 Social disparities …

Background: Chimeric Antigen Receptor (CAR) T-cell therapy is a relatively novel treatment
in Canada for relapsed and refractory leukemias and lymphomas. Limited evidence is …

Melanoma, an aggressive malignant tumor originating from melanocytes in humans, is on
the rise globally, with limited non-surgical treatment options available. Recent …

Chimeric antigen receptor (CAR) T-cell therapy has transformed the care of patients with
relapsed/refractory B-cell derived hematologic malignancies. To date, six CAR T-cell …